Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest Angiotech Pharmaceuticals Inc. Stories

2011-02-09 11:30:00

VANCOUVER, Feb. 9 /PRNewswire/ - Angiotech Pharmaceuticals, Inc. ("Angiotech" or the "Company") today announced that it has reached an agreement (the "Fifth Extension Agreement") with the holders (the "Consenting Noteholders") of a majority of the Company's outstanding 7.75% Senior Subordinated Notes (the "Subordinated Notes") to extend certain deadlines outlined in the previously announced Recapitalization Support Agreement, dated as of October 29, 2010 (as amended, the "Support...

2011-01-28 16:00:00

VANCOUVER, Jan. 28 /PRNewswire/ - Angiotech Pharmaceuticals, Inc. (TSX: ANP) ("Angiotech " or the "Company") today announced that, further to its news release issued earlier today, the Company and certain of its subsidiaries have voluntarily commenced proceedings under the Companies' Creditors Arrangement Act (the "CCAA") in order to continue implementation of its previously announced recapitalization transaction, having obtained an Initial Order from the Supreme Court of British...

2011-01-26 11:15:00

VANCOUVER, Jan. 26 /PRNewswire/ - Angiotech Pharmaceuticals, Inc. (TSX: ANP) ("Angiotech" or the "Company") today announced it had received a Notice of Termination (the "Notice") from Rex Medical L.P. ("Rex") with respect to the License, Supply, Marketing and Distribution Agreement between Angiotech US and Rex, dated March 13, 2008 (as amended, the "Agreement").  In the Notice, Rex gives notice of its termination of the Agreement. The Notice of Termination alleges that Angiotech...

2011-01-13 11:00:00

VANCOUVER, Jan. 13 /PRNewswire/ - Angiotech Pharmaceuticals, Inc. (OTCQB: ANPI, TSX: ANP) ("Angiotech" or the "Company") today announced that trading of shares of the Company's common stock will be transferred from the Nasdaq Stock Market ("Nasdaq") to the OTCQB(TM) Marketplace effective January 13, 2011. As previously disclosed on January 5, 2011, Angiotech received a notice from Nasdaq stating Angiotech has not regained compliance with Nasdaq's Listing Rule 5450(a)(1) within the 180...

2010-11-29 11:30:00

VANCOUVER, Nov. 29 /PRNewswire/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) ("Angiotech") announced it has entered into a private label product supply agreement with Hologic, Inc. (NASDAQ: HOLX) ("Hologic") for soft tissue biopsy instruments manufactured by Angiotech.  The initial term of the supply agreement is for three years with automatic renewals (subject to certain conditions) for additional periods of three years each.  The agreement is specific to...

2010-11-09 04:00:00

Updated and Amended Credit Facility and Forbearance Agreement with Wells Fargo Capital Finance, LLC Completed Facility to Provide Angiotech up to $35 Million of Liquidity during Recapitalization Transaction Process VANCOUVER, Nov. 9 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that it had released its financial results for the third quarter ended September 30, 2010. In addition, Angiotech also announced today that it had...

2010-10-29 19:00:00

VANCOUVER, Oct. 29 /PRNewswire-FirstCall/ - In September 2010, Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP) ("Angiotech" or the "Company") entered into confidentiality, non-disclosure and non-use agreements (as amended, the "Confidentiality Agreements") with certain beneficial holders of and/or investment advisors with investment discretion over the Company's 7.75% Senior Subordinated Notes (the "Subordinated Noteholders") in order to facilitate discussion of a possible...

2010-10-06 07:00:00

Angiotech Intends to Vigorously Defend Against the Claims VANCOUVER, Oct 6 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSE: ANP) ("Angiotech" or the "Company") today announced that on October 4, 2010, the Company was notified that QSR Holdings, Inc. ("QSR"), as the representative for the former stockholders of Quill Medical, Inc. ("QMI"), made a formal demand to the American Arbitration Association naming as...

2010-07-30 07:00:00

VANCOUVER, July 30 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced its financial results for the second quarter ended June 30, 2010. "We are pleased to report continued quarter over quarter growth in product sales, driven primarily by our most innovative Proprietary Medical Products," said Dr. William Hunter, President and CEO of Angiotech. "In addition, we are encouraged by sales trends for our Base Medical Products, which continued to show...

2010-07-28 15:23:00

VANCOUVER, July 28 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) ("Angiotech") and partner Athersys, Inc. (NASDAQ: ATHX) announced positive results from its phase I clinical trial of MultiStem(R), its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. The study results, which represent at least four months of post-treatment patient data, demonstrate that...